Regeneron Provides Initial Data on Two Antibody Product Candidates …

In an interim efficacy analysis of a randomized , double-blind, four-arm, placebo- controlled Phase 2 trial , in 217 patients with osteoarthritis of the knee, REGN475 demonstrated significant improvements at the two highest doses tested as … In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout , diseases of the eye (wet …

See the original post here: 
Regeneron Provides Initial Data on Two Antibody Product Candidates …

No comments yet.

TOP